Publications by authors named "S Frigstad"
Background And Aims: The emergence of biologic therapy has coincided with a decline in surgery rates for Crohn's disease (CD). This study aims to describe the disease course, including intra-abdominal surgery rates, biologic therapy use, and variables associated with biologic therapy initiation in a cohort of newly diagnosed CD patients.
Methods: The Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) III study is a population-based inception cohort study.
Background And Aims: Fatigue is commonly observed in Crohn's disease (CD) and ulcerative colitis (UC), but its association to achieving remission is not clearly established. In this study we describe the odds for fatigue in patients with CD/UC one year after diagnosis based on different definitions of remission and identified factors associated with chronic fatigue (CF) among patients in endoscopic/radiological remission.
Methods: Patients ≥18 years with CD/UC were recruited from the IBSEN III cohort.
Article Synopsis
- A cross-sectional study in Norway examined adverse events related to colonoscopy in a randomized colorectal cancer screening trial, involving over 10,000 participants.
- Out of those, 2.4% experienced adverse events, ranging from mild to severe, with the most common issues being gastrointestinal bleeding and abdominal pain.
- Key risk factors for adverse events included older age, female sex, and specific medical treatments, highlighting the importance of awareness for endoscopists to reduce risks.
Surgical treatment of benign colorectal polyps 2008-21.
Tidsskr Nor Laegeforen
September 2024
Background: Colorectal cancer is one of the most common forms of cancer in Norway, and typically develops from colorectal polyps. For benign colorectal polyps, endoscopic removal is recommended to avoid unnecessary surgery. This study identifies the extent of surgical treatment of benign polyps in the period 1 January 2008-31 December 2021.
View Article and Find Full Text PDFArticle Synopsis
- The introduction of biologic therapies combined with a 'treat-to-target' strategy may have positively influenced the progression of ulcerative colitis (UC) in newly diagnosed patients.
- A study involving 877 adult patients with UC showed that a significant portion was in remission after one year, with low rates of disease progression and colectomy.
- The findings suggest that early treatment with biologics correlates with better outcomes, highlighting the importance of timely intervention in managing UC.